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. Introduction
Haematological malignancies (HM) represent over 6% of all cancers occurring in the European population. It is estimated that more than 232,000 new cases of HM occurred in forty European countries in 2012 and over 120,000 persons died of these conditions. HM affect all age groups, to a different extent (Fig. 1) . The five-year prevalence estimate exceeds 575,000 patients [1] . Timely and correct diagnosis is indispensable for efficient disease control.
Difficulties arise for cancer registries in the registration of multiple tumours, in particular, haematological malignancies (HM) which may transform or progress in the course of the disease. HM are thought to arise by genetic change (malignant transformation) of a single cell originally present in bone marrow, thymus or the lymphoid system. The transformed cell undergoes clonal replication and expansion. In many cases further genetic changes take place and the subsequent clones become more aggressive, or transform into a different tumour type [2] . Examples of transformation include myelodysplastic syndrome to acute myeloid leukaemia. HM may be diagnosed at any stage in the process of malignant transformation.
Better understanding of the natural history of these diseases, together with rapid advances in methods for diagnosis and prognosis prediction, has led to improvement in HM classification. These have been reflected in updates to the International Classification of Diseases for Oncology [3] [4] [5] . The Haemacare manual [6] provides useful clinical information on HM and their coding and helps explain decision making processes. While excellent for clinicians, it lacks the specific practical advice required by population based or clinical registries for registration of evolution or transformation of HM.
This work which should be considered supplementary to the Haemacare manual and takes account of new morphological codes [5] was undertaken by a Working Group (WG) of Work Package 3 of Eurocourse (www.eurocourse.org) following terms of reference prepared by the Steering Committee of the European Network of Cancer Registries (ENCR) to: a) Define how cancer registries should record HM undergoing transformation from a tumour with uncertain behaviour (coded /1) to malignant tumour (behaviour coded /3), or from one malignant histology to another and b) Provide rules for recording and counting multiple diagnoses of HM in the registry database
Methods
For this work the WG firstly reviewed the available information on the subject. This included existing ENCR rules [7] , the Haemacare manual [6] , rules for coding multiple HM from European registries represented in the WG (United Kingdom (UK), Spain, France, Italy and The Netherlands), as well as the Hematopoietic and Lymphoid Database from the Surveillance, Epidemiology, and End Results (SEER) Program from the United States [8] . Based on the existing information new recommendations were made, as well as a list with morphology combinations to support the decision whether to code one or two HM. The latter list was based on an (unpublished) list from the Netherlands and adapted using the expert's opinion of the WG members.
Recommendations

Multiple data sources should be used to register HM
Except for lymphomas, most of the myelodysplastic disorders, myeloproliferative neoplasms and leukaemias may not have a solid tissue diagnosis and definitive diagnosis will be made on haematological preparations alone. Therefore, in addition to histopathology, cytology, clinical records and death notifications, registration of HM requires data on blood, bone marrow, flow cytometry, molecular and cytogenetic tests from haematology and designated molecular laboratories. These specific data sources are required to ensure complete case ascertainment and accurate morphological classification.
As already mentioned in the Haemacare manual [6] , cytogenetic analysis is essential for establishing the diagnosis of subgroups of acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS) and chronic myeloid leukaemia (CML), and for identifying other myeloproliferative and lymphoproliferative disorders e.g. through the JAK-2 mutation to confirm polycythaemia vera, t(11;14) translocation to confirm mantle cell lymphoma or the t(8;14) translocation to confirm Burkitt lymphoma. Further detail and examples of these are available in the Haemacare manual [6] .
Registration of multiple notifications
After a newly diagnosed haematological malignancy has been registered, additional information obtained by cancer registries for the same patient provides several options for registration. a. Same tumour, but with a more specific or revised diagnosis b. Transformation c. New tumour registration Table 1 shows for the myelodysplastic syndromes (MDS) potential combinations of morphology codes that can be considered as the same tumour or a transformation. Unspecific codes are underlined. A more extensive table containing all haematological malignancies is available in the appendix. In general, different diagnoses within a diagnostic group of the World Health Organisation (WHO) Classification (such as MDS) will relate to the same tumour. In all cases, the most specific diagnosis should be registered with clinical opinion having the final call. Combinations which are not in the table can be considered as two separate tumours.
Same tumour but with a more specific or revised diagnosis
In HM it is not uncommon that different diagnostic specimens result in a different diagnosis. In general, such different diagnoses within a diagnostic group of the WHO Classification will relate to the same tumour [4] . The most specific morphology code should be registered.
For example, if a patient's medical file has a 'myelodysplastic syndrome' (morphology code 9989), and the laboratory report gives the specific diagnosis of 'refractory anaemia with excess blasts' (morphology code 9983), the latter morphology code should be registered, as according to Table 1 9989/3 and 9983/3 probably refer to the same tumour and 9983/3 is the most specific code (not underlined).
When a pathological specimen/slide is reviewed by an expert pathologist/haematologist/cytologist the expert opinion is considered the definitive diagnosis, but the revision of the diagnosis will not change the already assigned date of incidence. For example, if the initial diagnosis is 'refractory anaemia' (morphology code 9980), while after revision the diagnosis is modified into 'myelodysplastic syndrome with isolated del(5q)' (morphology code 9986), the latter morphology code should be registered.
Transformation
When a HM transforms into a new morphological entity, only the first tumour is to be considered as incident: the transformed tumour must not be counted as a new tumour and therefore not be included in the incidence statistics.
If the transformation occurs within three months after the incidence date initially chosen, the morphology code of the transformed malignancy should replace that of the first tumour and be recorded as the first primary and not a transformation. If the transformation occurs outside the three month window, then the morphology code should be recorded as that of the initial malignancy and the morphology of the transformed malignancy, while noted in the registry, must not be included in incidence estimates.
Preferably, registries should record information on original as well as transformed tumours. The transformation/multiple primary rules should then be applied only at the time of analysis. The record of the transformed malignancy should, if possible, also be flagged as transformation. In accordance with the Haemacare Table 1 Combinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation (only combinations with myelodysplastic syndrome are shown; see the appendix for other combinations).
Initial diagnosis
Morphology code of the first HM Morphology codes probably referring to the same tumour as the first HM)
Morphology codes referring to potential transformation of the first HM (see note 3) For example, if six months after the diagnosis of a refractory anaemia with excess blasts an acute myeloid leukaemia is diagnosed, this should be considered as a transformation, if within three month period then it would be considered as a first registration of acute myeloid leukaemia with no transformation and date of diagnosis that of the diagnosis of the refractory anaemia. (see Table 1 ).
A new tumour registration
This occurs when i. a HM with malignant behaviour (code /3) occurs after a previous haematological disease with uncertain behaviour (code /1) (the later diagnosed malignant HM should be registered as a new tumour with a new incidence date) or ii. the change is not a transformation or a revised diagnosis of an existing tumour or iii. a clinical opinion regarding a new tumour is available and the details of that decision is recorded.
For example, irrespectively of the time interval between the two diagnoses, two separate tumours should be registered in the case of Hodgkin lymphoma following a myelodysplastic syndrome, (the combination is not in Table 1 ).
Survival analysis of multiple tumours/transformations
Regular survival analysis methods do not necessarily apply in the case of patients with HM where transformations have occurred as the patient has to be alive until the diagnosis of multiple tumour or transformation occurs. The information of these changes may be used as time-dependent covariates. There are special methods for such multiple tumour analyses [10] .
The basis of diagnosis follows the ENCR recommendations [7]
In general, code 5 (cytological examination of peripheral blood, bone marrow aspirate or other aspirates) and code 7 (histology of lymph node or tissue biopsy including trephine bone marrow biopsy) are most appropriate for HM. Blood tests e.g. smears should be considered to have the same standing as 'cytology' (code 5).
Code 1 (physical examination, diagnosis made before death, but without the support of diagnostic modalities) and Code 6 (Histology of metastasis) are not applicable to haematological malignancies. Code 4 (specific tumour marker) is applicable for multiple myeloma diagnosed with other criteria using data on serum immunoglobulins or light chain urinary excretion. Code 2 (instrumental/surgical examination) may be applicable exclusively for brain lymphoma
Incidence date
The ENCR recommendations for coding of incidence date should be followed for assigning the incidence date for HM for the purposes of cancer registration [9] .
When a pathological specimen/slide is reviewed by a second expert pathologist, the expert opinion is considered the definitive diagnosis, but the original date of incidence does not change.
Discussion
This paper provides the guidelines necessary for correct recording of HM, so that the resulting population-based data may monitor the incidence and outcome with as much precision as possible. These data inform the priorities for clinical research as well as health policy decisions.
There are over 600 population-based cancer registries internationally, 300 included in Cancer Incidence in V Continents [11, 12] , all recording data according to agreed rules on malignant and premalignant diseases for defined populations. Some of them specialise in registration of HM only, either in childhood or in all ages. They monitor disease levels and changes over time, facilitate scientific study of disease causes and patterns, including alleged clusters and enable monitoring of patient care and outcomes including survival. These cancer registries have developed worldwide collaboration and regional networks. Standardised data recording, processing and reporting are indispensable for comparative studies across populations and over time. Presented recommendations are in line with the current classification standards, including pathological classification of HM covered in the WHO, Classification of Tumours of the Haematopoietic and Lymphoid tissue [4] , the ICD-O-3 [3] and its update of 2011 [5] . The Haemacare manual provides useful clinical information on HM and their coding and helps explain decision making processes [6] . The current work will supplement the publications mentioned above with specific practical advice for the populationbased cancer registries as well as all primary data providers and may be useful also for clinical cancer registries. It highlights the need for standardised rules for registration, coding and selecting of HMs for analyses.
Incidence statistics serves a basis for aetiological studies, therefore only the first incident tumour will be most of interest. However, to allow for changes in multiple primary rules over time and various research interests, it is important that the registries retain all available data on transformed tumours or successive diagnoses in their databases. Counting only one tumour will also help to keep coherence with the mortality statistics.
Inclusion of cases in the analysis of survival will depend on the question asked. To produce populationbased estimates of survival, the first tumour will most often be of interest. However, data should also allow for analysing survival of patients with specific succession of neoplasms or transformations, using the appropriate statistical methods.
The ENCR recommendations for recording of HM were developed by a dedicated working group during 2012 (full report at www.encr.eu) and endorsed by the Steering Committee of ENCR in April 2013. They complement the series of ENCR recommendations on registration practices released between 1995 and 2002 [7] . Their implementation will improve the comparability of incidence and survival data for HM across cancer registries and over time. 
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Appendix
Combinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation. 
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